Database : HANSEN Search on : HANSENIASE/TERAP [Subject descriptor] References found : 937 [refine] Displaying: 1 .. 20   in format [Detailed]

page 1 de 47

go to page

1 / 937

HANSEN

select to print

Id: 19942 Author: Toral, Esteban Moreno; Diaz, M. Teresa Lopez. Title: The influence of the San Lazaro Hospital of Seville in the creation and management techniques of the "Lazaretto" Hospitals in the Americas. Source: Int. J. Lepr;65(2):252-256, Jun. 1997. . Abstract: The San Lazaro Hospital of Seville that was established in the middle of the 13th century was one of the most important in Spain and Europe throughout nearly eight centuries in terms of caring for leprosy patients. In the 1930s the exclusive treatment of leprosy patients ceased and San Lazaro became a general hospital. The Spanish Crown (Alfonso X) accorded certain privileges and rules to the hospital which also were conferred by subsequent monarchs. These rules and ordinances contributed to the establishment and functioning of many lazarettos throughout the Americas of which we have documentation, notably those of Santo Domingo, Tlaxplana (Mexico City), Lima, Cartagena de Incias, La Habana, and Yucatan. (AU)^ien. Descriptors: Hanseníase/hist Hanseníase/terap Hospitais de Dermatologia Sanitária de Patologia Tropical/hist Location: BR191.1

2 / 937

HANSEN

select to print

Id: 19892 Author: Anon. Title: Recomendações para pessoas atingidas pela hanseníase / ? Source: In: Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica.Autocuidado em Hanseníase: face, mãos e pés^ipt. Brasília, Editora do Minist´rio da Saúde, 2010. p.70-70. Descriptors: Hanseníase/prev Hanseníase/reabil Hanseníase/terap Location: BR191.1, B736a

3 / 937

HANSEN

select to print

Id: 19887 Author: Anon. Title: Controlando a hanseníase: um desafio para o SUS no Instituto Lauro de Souza Lima / ? Source: In: São Paulo(Estado). Secretaria de Estado da Saúde. Coordenadoria de Controle de Doenças.Vigilância em Saúde: 20 anos SUS-SP^ipt. São Paulo, s.n, 2008. p.51-61ilus. Descriptors: Hanseníase/epidemiol Hanseníase/prev Hanseníase/terap Location: BR191.1, S63v

4 / 937

HANSEN

select to print Texto Completo-en

Id: 19864 Author: Anon. Title: Rehabilitation. Source: Int. J. Lepr;66(4):138A-143A, Dec. 1998. . Conference: Present in: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998. Descriptors: Hanseníase/reabil Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4abs12.pdf / en Location: BR191.1

5 / 937

HANSEN

select to print Texto Completo-en

Id: 19863 Author: Anon. Title: Psycho-Social. Source: Int. J. Lepr;66(4):127A-137A, Dec. 1998. . Conference: Present in: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998. Descriptors: Hanseníase/psicol Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4abs11.pdf / en Location: BR191.1

6 / 937

HANSEN

select to print Texto Completo-en

Id: 19836 Author: Richardus, J. H; Virmond, M. Title: Report of workshop on prevention of disability. Source: Int. J. Lepr;66(4):576-576, Dec. 1998. . Conference: Present in: International Leprosy Congress, 15, Beijing, 07-12 Sept. 1998. Descriptors: Hanseníase/compl Hanseníase/terap Pessoas com Deficiência/reabil Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n4/v66n4repcur01.pdf / en Location: BR191.1

7 / 937

HANSEN

select to print Texto Completo-en

Id: 19774 Author: Anon. Title: Current literature. Source: Int J Lepr;57(2):564-597, June 1989. . Descriptors: Hanseníase/diag Hanseníase/prev Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2curlit.pdf / en Location: Br191.1

8 / 937

HANSEN

select to print Material Projetável-pt

Id: 19752 Author: Fundação Oswaldo Cruz. Canal Saúde*. Title: Hanseníase^ipt Leprosy- Source: Rio de Janeiro; Fiocruz; s.d. . Descriptors: Hanseníase/diag Hanseníase/prev Hanseníase/fisiopatol Hanseníase/terap Electronic Medium: http://www.canal.fiocruz.br/video/index.php?v=hanseniase / pt

9 / 937

HANSEN

select to print Texto Completo-en

Id: 19734 Author: Grosset, Jacques H; Guelpa-Lauras, Claire-Cécile; Bobin, Pierre; Brucker, Gilles; Cartel, Jean-Louis; Constant-Desportes, Monique; Flageul, Béatrice; Frédéric, Micheline; Guillaume, Jean-Claude; Millan, Jacques. Title: Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Source: Int J Lep;57(3):607-614, sept. 1989. ^btab. Abstract: Among 39 strains of Mycobacterium leprae isolated from patients with multibacillary leprosy who relapsed after treatment with rifampin (RMP), 22 strains were resistant to RMP and 17 were susceptible. All of the RMP-resistant strains were recovered from patients who had been treated with more than 50 doses of RMP, usually given as monotherapy. RMP-susceptible strains were recovered from only six patients who had received more than 50 doses of RMP, and from 11 patients who had received no more than seven doses. The median time to relapse after the beginning of RMP therapy was 9 years (range 1-12 years) among the patients harboring RMP-resistant strains of M. leprae, and the median time to relapse after discontinuation of RMP treatment was 7 years (range 1-11 years) among the patients harboring RMP-susceptible strains. These data suggest that monotherapy with more than a few doses of RMP can be responsible for the emergence of RMP-resistant strains of M. leprae, thus emphasizing the need to employ RMP only in combination with other effective drugs in the chemotherapy of multibacillary leprosy. Descriptors: Hanseníase/quimioter Hanseníase/terap Rifampina/uso terap Limits: Humanos Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n3/v57n3a02.pdf / en Location: Br191.1

10 / 937

HANSEN

select to print Material Projetável-pt

Id: 19732 Author: Fundação Oswaldo Cruz. Canal Saúde*. Title: Hanseníase: sala de convidados^ipt Leprosy: guest room- Source: Rio de Janeiro; Fiocruz; s.d. . Descriptors: Hanseníase/diag Hanseníase/prev Hanseníase/terap Electronic Medium: http://www.canal.fiocruz.br/video/index.php?v=hanseniase-936 / pt Location: Br191.1

11 / 937

HANSEN

select to print Texto Completo-en

Id: 19718 Author: Agrawal, Sudha; Joshi, Arun; Jacob, Mary; Sah, Shatrughan P; Agarwalla, Arun; Garg, Vijay Kumar. Title: Leprosy at the age of 141 years: a case report. Source: Int. J. Lepr;67(4):471-473, Dec., 1999. ilus. Descriptors: Hanseníase/diag Hanseníase/quimioter Hanseníase/fisiopatol Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n4/v67n4cor01.pdf / en Location: BR191.1

12 / 937

HANSEN

select to print Texto Completo-en

Id: 19710 Author: Ebenezer, Gigi J; Job, Charles K. Title: Histopathological activity in paucibacillary leprosy patients after ROM therapy. Source: Int. J. Lepr;67(4):409-413, Dec., 1999. ilus, tab, graf. Abstract: Histopathological activity was assessed in the skin tissue of 13 skin-smear negative, borderline tuberculoid leprosy patients after administration of a single dose of ROM (rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg) therapy. Biopsies taken just before therapy showed Mycobacterium leprae to be present in eight cases. After 6 months, only three showed granulomatous lesions and others showed only resolving or inactive lesions. Acid-fast bacilli (AFB) persisted in the nerves of three cases. At the end of 12 months, granulomas persisted in 2 out of 13 (15%) patients. No bacilli, however, were detected in any of them at the end of 12 months. This study demonstrated that 12 months after a single dose of ROM granuloma cleared in 85% of the patients and AFB were absent in all of them. (AU)^ien. Descriptors: Hanseníase/patol Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n4/v67n4a06.pdf / en Location: BR191.1

13 / 937

HANSEN

select to print Texto Completo-en

Id: 19706 Author: Chen, Xiang-Sheng; Li, Wen-Zhong; Jiang, Cheng; Ye, Gan-Yun. Title: Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy. Source: Int. J. Lepr;67(4):379-387, Dec., 1999. tab, graf. Abstract: Based upon the data from the Chinese National System for Leprosy Surveillance, this paper reports on the relapses in 47,276 leprosy patients cured by or released from WHO-recommended multidrug therapy (WHO/MDT). The overall relapse rate was 0.73/1000 patient-years (PY). There was a statistically significant difference in the relapse rates of WHO/MDT-MB (0.61/1000 PY) and WHO/MDT-PB (1.04/1000 PY) (chi 2 = 15.7, p < 0.01) patients. For multibacillary (MB) patients, the relapse rate in patients treated with fixed-duration MDT (0.56/1000 PY) was comparable with that in patients treated with MDT until skin-smear negativity (0.73/1000 PY) (chi 2 = 2.20, p > 0.05). Our present study suggests that fixed-duration MDT is a cost-effective regimen for the treatment of leprosy in China. The present results also show that relapse of leprosy is acceptably low and has not yet become a serious clinical or public health problem but, based upon the incubation of relapse in MDT patients, it is necessary to encourage annual follow up for at least 5 years for paucibacillary (PB) and 10 years for MB patients after being released from WHO/MDT. (AU)^ien. Descriptors: Hanseníase/quimioter Hanseníase/terap China/etnol China/epidemiol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n4/v67n4a02.pdf / en Location: BR191.1

14 / 937

HANSEN

select to print Texto Completo-en

Id: 19705 Author: Chen, Xiang-Sheng; Li, Wen-Zhong; Jiang, Cheng; Ye, Gan-Yun. Title: Studies on risk of leprosy relapses in China: relapses after treatment with dapsone monotherapy. Source: Int. J. Lepr;67(4):371-378, Dec., 1999. tab, graf. Abstract: Based upon the data from the Chinese National System for Leprosy Surveillance, this paper reports on the relapses in 297,343 leprosy patients [multibacillary (MB) 106,518, paucibacillary (PB) 190,825] cured by dapsone monotherapy. A total of 11,055 (MB 8675, PB 2380) patients relapsed during an accumulated follow-up period of 4,229,050 patient-years (PY), giving an overall relapse rate of 3.72 per 100 cases or 2.61 per 1000 PY, i.e., 8.14% or 5.91 per 1000 PY over an average follow-up period of 13.8 +/- 8.4 years in MB patients and 1.25% or 0.86 per 1000 PY over an average period of 14.5 +/- 8.9 years in PB patients. For either the overall relapse rate per 100 cases or per 1000 PY, the differences between MB and PB patients were statistically significant, except during 36-40 years of follow up. For both MB and PB patients, the relapse rates showed consistently significant decreases year by year, particularly in PB patients whose relapse rate per 1000 PY was 1.21 in year 10 of follow up; whereas it remained more than 10 per 1000 PY in MB patients. In view of that, the overall relapse rates in MB and PB patients cured by dapsone monotherapy were acceptably low, and most of these patients have been followed up for more than a mean incubation period of observed dapsone relapse. Along with the further extension of follow up, the risk of relapse in dapsone-cured patients will not be expected to increase. This conclusion should be considered when planning policy for the management of patients released from dapsone monotherapy. (AU)^ien. Descriptors: Hanseníase/quimioter Hanseníase/epidemiol Hanseníase/terap Dapsona/uso terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n4/v67n4a01.pdf / en Location: BR191.1

15 / 937

HANSEN

select to print Texto Completo-en

Id: 19700 Author: Vadher, Atul. Title: Correspondence: Patient Treatment Compliance in Leprosy; a Reply. Source: Int. J. Lepr;63(1):120-121, 1995. . Descriptors: Hanseníase/diag Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1995/pdf/v63n1/v63n1cor13.pdf / en Location: BR191.1

16 / 937

HANSEN

select to print Texto Completo-en

Id: 19699 Author: Ellard, Gordon A. Title: Correspondence: Patient Treatment Compliance in Leprosy; an Unjustifiably Critical Review. Source: Int. J. Lepr;63(1):117-120, 1995. ^btab. Descriptors: Hanseníase/diag Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1995/pdf/v63n1/v63n1cor12.pdf / en Location: BR191.1

17 / 937

HANSEN

select to print Texto Completo-en

Id: 19675 Author: Ponninghaus, Jorg M; Boerrigter, Gjalt. Title: Are 18 Doses of WHO/ MDT Sufficient for Multibacillary Leprosy; Results of aTrial in Malawi. Source: Int. J. Lepr;63(1):1-7, 1995. ^btab, ^bgraf. Abstract: A trial comparing 18 monthly and 30 monthly doses of the World Health Organization-recommended multidrug therapy (WHO/MDT) in 305 multibacillary leprosy patients in Malawi is described. Patients were randomly allocated to one of the two regimens at the time of taking the 18th supervised dose of WHO/MDT. The mean follow-up period was 3 years (maximum 6 years). No relapse was observed in either group. The cumulative probabilities of remaining slit-skin smear positive were significantly higher among patients receiving only the 18 monthly doses of WHO/MDT, but reached zero at month 60 of follow up. The percentage of patients who developed new disabilities during the trial period was similar in both groups. However, the overall percentage of patients who developed new disabilities (50/305, 16.4%) remains disturbingly high. On the whole, the results of the trial argue in favor of 18 monthly doses of WHO/MDT taken within 24 months as being sufficient for the treatment of multibacillary leprosy. Descriptors: Hanseníase/quimioter Hanseníase/fisiopatol Hanseníase/terap Limits: Humanos Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1995/pdf/v63n1/v63n1a01.pdf / en Location: BR191.1

18 / 937

HANSEN

select to print Texto Completo-en

Id: 19668 Author: Revankar, C. R; Pai, V. V; Samy, M. S. Antony; Ganapati, R. Title: Single-dose treatment for paucibacillary leprosy; field implications. Source: Int. J. Lepr;67(3):312-314, Sept., 1999. tab. Descriptors: Hanseníase/quimioter Hanseníase/fisiopatol Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n3/v67n3cor05.pdf / en Location: BR191.1

19 / 937

HANSEN

select to print Texto Completo-en

Id: 19667 Author: Ganapati, R; Revankar, C. R; Pai, V. V; Kingsley, S. Title: Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up. Source: Int. J. Lepr;67(3):308-309, Sept., 1999. graf. Descriptors: Hanseníase/quimioter Hanseníase/fisiopatol Hanseníase/terap Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n3/v67n3cor04.pdf / en Location: BR191.1

20 / 937

HANSEN

select to print Texto Completo-en

Id: 19658 Author: Sharma, Pankaj; Kar, Hemant K; Misra, Radhey S; Mukherjee, Ashok; Kaur, Harvinder; Mukherjee, Rama; Rani, Rajni. Title: Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with mycobacterium w antileprosy vaccine. Source: Int. J. Lepr;67(3):250-258, Sept., 1999. tab. Abstract: A vaccine based on autoclaved Mycobacterium w was administered, in addition to standard multidrug therapy (MDT), to 157 bacteriologically positive, lepromin-negative, multibacillary leprosy patients supported by a well-matched control group of 147 patients with similar type of disease who received a placebo injection in addition to MDT. The MDT was given for a minimum period of 2 years and continued until skin-smear negativity, while the vaccine/placebo was given at 3-month intervals up to a maximum of 8 doses in the initial 2 years. The overall incidence of type 1 and type 2 reactions and neuritis during treatment and follow up was nearly equal in the patients in the vaccine and placebo groups; the differences were not statistically significant. The occurrence of disabilities, such as anesthesia, trophic ulcers, claw hand and grade 3 deformities, were not different statistically in the vaccine and placebo groups, an observation valid both for deformities present at induction and for those which developed during the course of therapy and surveillance. A statistically significant difference was observed in the recovery of newly developed trophic ulcers; recovery was quicker in the vaccine group. The recovery rate for motor deformities was marginally higher in the vaccine group, although not significant (p = 0.068) statistically. There was a statistically significant reduction in the incidence of grade 3 deformities following MDT with and without immunotherapy. To conclude, the addition of vaccine to MDT did not precipitate neuritis or deformities over and above that encountered with MDT alone, although it did accelerate bacteriological clearance, histopathological upgrading, conversion to lepromin positivity, and clinical improvement. (AU)^ien. Descriptors: Hanseníase/quimioter Hanseníase/terap Mycobacterium leprae/genet Mycobacterium leprae/imunol Electronic Medium: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1999/pdf/v67n3/v67n3a04.pdf / en Location: BR191.1

---

page 1 de 47

go to page

Refine the search

Database : HANSEN

Advanced form

Search for : Free form

		Search	in field
1			WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
2	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type
3	and or and not		WordsTitle wordsAbstract wordsAuthorInstitutional authorSubject descriptorLimitsLanguageCountry, year publicationJournalType of literatureBibliographic levelMonography in seriesPublication typeConferenceUnique identifierLocationElectronic supportEntry dateRecord type

Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO Latin American and Caribbean Center on Health Sciences Information